KeyBanc Capital Markets has upgraded Solventum to Overweight, citing a valuation gap within the MedTech sector. The brokerage believes the stock's recent underperformance has created opportunities. They set a $97 price target, which is based on 14x its 2027 earnings estimate. The stock currently trades at 11.4x, placing it in the bottom quintile of its peer group.

KeyBanc's positive outlook stems from supportive fourth-quarter indicators, including positive preannouncements and favorable commentary from companies like Johnson & Johnson. The firm noted the MedTech sub-sector lagged the broader market in the last two years, eroding its historical premium. Hospital volumes showed mid- to high-single-digit growth. They also expect increased capital markets activity in 2026.

For Solventum specifically, KeyBanc sees the spin-off from 3M progressing well. The firm points to new product launches, growth-focused acquisitions, and a more aggressive capital allocation strategy. They believe concerns around 2026 guidance might be overstated. These factors could enable Solventum to achieve its 4–5% organic growth goal.

This upgrade is a vote of confidence in Solventum's future performance. It also reflects broader optimism about the MedTech sector's prospects. Investors should watch for further developments in the company’s spin-off progress and any updates on capital allocation strategies. The M&A environment is also worth monitoring.